Predictive value of tumor-infiltrating lymphocytes (TILs) and programmed cell death-ligand 1 (PD-L1) expression in breast cancer patients treated with neoadjuvant chemotherapy

Rashed, Hayam E.; muhammad, shireen; Sameh, Reham; Elsebai, Eman; Nawar, Nashwa; Abdelhamid, Mohamed I.; Abdel‐Aziz, Lobna M.

doi:10.1016/j.senol.2020.12.006

Cited by 2 publications

(2 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The highest expression of TILs was detected in triple-negative breast cancer, and the high expression of CD3 in triple-negative cancer patients is related to the aggressiveness of this kind of cancer. These results are compatible with Rashed et al .’s findings 7 .…”

Section: Resultsmentioning

confidence: 92%

Optimization of tissue microarray technique for breast cancer patients: a short communication

Harfouch,

Al-Shehabi,

Asaad

et al. 2023

Annals of Medicine &Amp; Surgery

View full text Add to dashboard Cite

Background: Tissue microarray (TMA) is a novel technique for studying different types of cancer tissues in one block. TMA is not yet established in Syria, so we aimed in this project to apply and set the most optimal conditions of TMA creation of breast cancer tissues at the Pathology Department of our institute. Materials and Methods: Eighty-eight blocks of breast cancer tissues were selected, considering the inclusion criteria. The tissue specimens of breast cancer patients were manually placed in the block by punching a core from a paraffin block, which was then released into a recipient block using a small trocar. Three different conditions were tested on the constructed TMA block. Results: We determined the most effective parameters that proved high quality: incubating the newly constructed block at a temperature of 43°C for 24 h in the oven and then cutting it the next day after cooling it to room temperature; also, cutting with a 5 μm thickness created the preferable stained slides later. CD3 staining showed high expression of tumor-infiltrating lymphocytes among triple-negative breast cancer patients and high expression of CD3 in triple-negative cancer patients. Conclusion: The optimization of parameters presented in our study resulted in perfect TMA generation and successful immunohistochemistry staining for cancer research at our institution.

show abstract

Section: Resultsmentioning

confidence: 92%

Optimization of tissue microarray technique for breast cancer patients: a short communication

Harfouch,

Al-Shehabi,

Asaad

et al. 2023

Annals of Medicine &Amp; Surgery

View full text Add to dashboard Cite

show abstract

“…Higher expression of PD-L1 on tumor cells was associated with the higher rates of pathologic complete response to durvalumab and chemotherapy [21] . In addition, PD-L1 expression was also associated with better pathological responses to NAT [22,23] , even to BC patients [24,25] . After NAT, PD-L1 expression on tumor cells was reported to be associated with tumor load and characteristics [26] .…”

Section: Discussionmentioning

confidence: 94%

Predictive Role of Peripheral Blood Lymphocyte And Cytokine Phenotypes in Patients with Operable Breast Cancer And Neoadjuvant Therapy: A Preliminary Study

Wu,

Ou,

Yuan

et al. 2024

Preprint

View full text Add to dashboard Cite

Background PD-L1 is an indicator for immunotherapy however, the detection is based on biopsy and affected by tumor heterogeneity and patients’ intolerance. This study aimed to explore convenient alternatives for PD-L1 tissue detection. Methods With 134 cases recruitment, the peripheral lymphocyte subtypes and cytokines was detected by flow cytometry and PD-L1 expression in tumor microenvironment (TME) was detected by immunohistochemistry and assessed by two qualified pathologists. Results The patients with positive PD-L1 expression had peripheral CD8+/CD28+ T lymphocytes 20% higher than those with negative expression (p = 0.008) with the area under the receiver operating characteristic curve (AUC) being 0.66 (p = 0.002). Among patients with positive PD-L1 expression and negative neoadjuvant therapy (NAT), peripheral CD8+/CD28+ T lymphocytes were 54% higher than those with negative expression (p = 0.003), with the AUC being 0.68 (p = 0.003). In patients receiving NAT, peripheral TNF-α (p = 0.010), increased from 0.45pg/ml to 0.64pg/ml in positive PD-L1 group, and the AUC was 0.79 (p = 0.012). Among breast cancer patients with negative NAT experience, 1% increase of peripheral CD8+/CD28+ T lymphocytes was associated with a 21% higher probability of positive PD-L1 expression (OR = 1.21, 95%CI = 1.06–1.37) and among patients with NAT, the OR of peripheral TNF-α > 0.5pg/ml was increased to 24.5 for positive TME PD-L1 expression (p = 0.008). Conclusion In breast cancer patients receiving NAT, peripheral TNF-α could be used to predict the TME PD-L1 expression, and in breast cancer patients without NAT, peripheral percentage of CD8+/CD28+ T lymphocytes could be used to predict the TME PD-L1 expression. These biomarkers should be further implemented in practice to guide the immunotherapy.

show abstract

Predictive value of tumor-infiltrating lymphocytes (TILs) and programmed cell death-ligand 1 (PD-L1) expression in breast cancer patients treated with neoadjuvant chemotherapy

Cited by 2 publications

References 15 publications

Optimization of tissue microarray technique for breast cancer patients: a short communication

Optimization of tissue microarray technique for breast cancer patients: a short communication

Predictive Role of Peripheral Blood Lymphocyte And Cytokine Phenotypes in Patients with Operable Breast Cancer And Neoadjuvant Therapy: A Preliminary Study

Contact Info

Product

Resources

About